This study aimed to evaluate treatment outcomes and safety of the combination therapy with different platinum-doublet chemotherapies, which showed that both regimens were associated with comparable efficacy (ORR, 70.5% vs. 2021 Jun 4) is the largest trial to date of concurrent anti–PD-(L)1 therapy plus concurrent chemoradiation therapy (cCRT) in patients with previously untreated, locally advanced, stage III NSCLC. A recent study by the same group titled Pembrolizumab plus Concurrent Chemoradiation Therapy in Patients with Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer the Phase 2 KEYNOTE-799 Nonrandomized Trial (JAMA Oncol.
To improve outcomes for patients with locally advanced non–small cell lung cancer who do not respond well to immunotherapy, efforts have been made at combining immunotherapy concurrently with chemoradiotherapy by Salma K. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
